Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nipocalimab
Therapeutic Area: Immunology Product Name: M281
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $6,500.0 million Upfront Cash: $6,500.0 million
Deal Type: Acquisition October 01, 2020
Details:
Johnson & Johnson's pipeline gains a new class of drugs. Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatment of autoantibody-driven autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nipocalimab
Therapeutic Area: Immunology Product Name: M281
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $6,500.0 million Upfront Cash: $6,500.0 million
Deal Type: Acquisition August 19, 2020
Details:
This acquisition gives Johnson & Johnson a major entry point into a new class of drugs. Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatment of autoantibody-driven autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
National Medical Products Administration (NMPA, China) approved IND application for HBM9161, a full-human antibody targeting neonatal Fc receptor (FcRn), to conduct a Phase 2/3 clinical trial in patients with Graves‘ ophthalmopathy (GO).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2020
Details:
Anti-FcRn antibody has potential to become portfolio-in-a-product; ITP trial is the first of several to study safety and efficacy in autoimmune disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nipocalimab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
Company is in active communication with clinical sites to be sure patients enrolled in studies have uninterrupted access to company's investigational drugs.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
